Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders

Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders

US Patent 7232813 · Granted Jun 19, 2007

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

17-beta HSD1 and STS inhibitors2013
Screening and treatment methods using IGS5 enzymes of the metalloprotease family2013
Screening and treatment methods using IGS5 enzymes of the metalloprotease family2013
Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H2012
Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H2012
17β-HSD1 and STS inhibitors2011
Screening and treatment methods using IGS5 enzymes of the metalloprotease family2011
Screening and treatment methods using IGS5 enzymes of the metalloprotease family2011
Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogen2010
Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H2010
Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H2010
N-oxides of venlafaxine and o-desmethylvenlafaxine as prodrugs2010